<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20848">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02835482</url>
  </required_header>
  <id_info>
    <org_study_id>AGC_2014-19</org_study_id>
    <nct_id>NCT02835482</nct_id>
  </id_info>
  <brief_title>Effect of Elevated Intraocular Pressure in Glaucoma Patients During Femtolaser Cataract Surgery</brief_title>
  <acronym>FEMTOHTO</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of the femtosecond laser causes an increase in the intraocular pressure (IOP)
      between 100 mm Hg and 200 mm Hg for a period of about 80 seconds (suction phase).

      If it is known that elevated IOP accelerates the degradation of retinal ganglion cells,
      whose axons form the optic nerve.

      No data has been published to date on potential adverse effects of femtolaser cataract
      surgery performed in patients with glaucomatous optic neuropathy.

      Since some time, spectral-domain optical coherence tomography (SD -OCT) provides a detailed
      analysis of ganglion cell complex (GCC) for which the loss is a marker of glaucomatous optic
      neuropathy. The resolution of this device, about a few microns, can detect even a tiny loss
      of this layer.

      The investigators propose to evaluate the effects of elevated intraocular pressure in
      glaucoma patients undergoing femtolaser cataract surgery, studying the GCC through SD-OCT.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2016</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In patient with glaucoma, measure of the thickness of the ganglion cell complex in the operated eye with femtosecond laser versus the operated eye with phacoemulsification.</measure>
    <time_frame>within the first 3 months after surgery</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Glaucoma</condition>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Patient with glaucoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient eligible for bilateral cataract surgery, with glaucoma. Each patient is his own control. The patient is treated with femtolaser surgery for one eye and with phacoemulsification for the other eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient without glaucoma</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient eligible for bilateral cataract surgery, without glaucoma. Each patient is his own control. The patient is treated with femtolaser surgery for one eye and with the phacoemulsification for the other eye.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Femtolaser surgery</intervention_name>
    <arm_group_label>Patient with glaucoma</arm_group_label>
    <arm_group_label>Patient without glaucoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Phacoemulsification</intervention_name>
    <arm_group_label>Patient with glaucoma</arm_group_label>
    <arm_group_label>Patient without glaucoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  scheduled bilateral cataract surgery

          -  bilateral known glaucoma confirmed at the preoperative consultation (glaucoma group)
             or absence of glaucoma in both eyes at confirmed the preoperative consultation
             (control group).

        Exclusion Criteria:

          -  ophthalmologic pathology known other than glaucoma

          -  diabetes

               -  untreated hypertension

               -  multiple sclerosis

               -  Graves' disease

               -  sarcoidosis

               -  patient taking toxic drug for the optic nerve and the retina

               -  neurodegenerative disease

               -  all general diseases that can affect the ocular structures

               -  eye surgery history

               -  patient's opposition to participation in the study, according to the law on
                  research into routine care

               -  absence of affiliation to social security or to universal medical coverage

               -  legally protected patient

               -  pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laurence Salomon, MD</last_name>
    <email>lsalomon@fo-rothschild.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondation ophtalmique Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Grise-Dulac, MD</last_name>
      <email>agrisedulac@fo-rothschild.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 7, 2017</lastchanged_date>
  <firstreceived_date>July 11, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
